Hemodynamic Completes Initial Phase 2 Clinical Study For Combination Hypertension Therapy
Hemodynamic has completed its initial Phase 2 clinical study of its compound (HTI-101), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. The 12-week double-blind
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.